[8-K] Kymera Therapeutics, Inc. Reports Material Event

Rhea-AI Filing Summary

Kymera Therapeutics announced that it reported its financial results for the quarter ended June 30, 2025 and furnished the related press release as Exhibit 99.1 to a Current Report on Form 8-K. The filing states the press release is being furnished and not deemed "filed" under the Exchange Act, and the cover page includes interactive data.

The Form 8-K text does not include the underlying financial figures; readers are referred to the furnished press release for detailed results. The report is signed by Nello Mainolfi, Ph.D., President and Chief Executive Officer, confirming the submission of the exhibit.

Positive

• Press release furnished as Exhibit 99.1 announcing financial results for the quarter ended June 30, 2025.
• Disclosure treatment clarified: the company explicitly states the exhibit is furnished and not "filed," aligning with standard Form 8-K practice.
• Authorized signature: report is signed by Nello Mainolfi, Ph.D., President and CEO.

Negative

• No financial figures in the Form 8-K text; the filing refers investors to the furnished press release for numeric results.
• Filing alone does not allow assessment of revenue, earnings, guidance, or other metrics because those details are not included in the 8-K.

Insights

Financial Analyst

TL;DR: Kymera furnished a press release with Q2 results, but the 8-K contains no financial figures, limiting assessment from the filing alone.

The filing confirms that Kymera reported results for the quarter ended June 30, 2025 and furnished the press release as Exhibit 99.1. The company explicitly states the exhibit is "furnished" and not "filed," which is a standard disclosure treatment and does not embed the figures in the 8-K text. Because no revenue, EPS, guidance, or other metrics are included within the Form 8-K itself, this filing notifies investors of the release but does not provide the numeric data needed to evaluate operating or financial performance.

Corporate Governance Expert

TL;DR: The 8-K documents procedural disclosure: a furnished press release and CEO attestation; it does not convey financial detail in the filing.

The document shows governance conformity: the company furnished a press release as Exhibit 99.1 and the report bears the signature of CEO Nello Mainolfi, Ph.D., indicating authorized submission. The statement that the exhibit is "furnished and shall not be deemed 'filed'" clarifies legal treatment under the Exchange Act. From a disclosure-process perspective, the filing fulfills reporting requirements but does not itself supply substantive financial metrics.

false000181544200018154422025-08-112025-08-11

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 11, 2025

KYMERA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-39460		81-2992166
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

Kymera Therapeutics, Inc.

500 North Beacon Street, 4th Floor

Watertown, Massachusetts 02472

(Address of principal executive offices, including zip code)

(857) 285-5300

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trade Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value per share	KYMR	The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition

On August 11, 2025, Kymera Therapeutics, Inc. announced its financial results for the quarter ended June 30, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form 8-K.

The information in this Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Exhibits

(d) Exhibits

Exhibit No.		Description
99.1		Press release issued by Kymera Therapeutics, Inc. on August 11, 2025, furnished herewith.
104		Cover Page Interactive Data

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		Kymera Therapeutics, Inc.
Date: August 11, 2025		By:		/s/ Nello Mainolfi
				Nello Mainolfi, Ph.D.
				President and Chief Executive Officer

FAQ

What did Kymera (KYMR) disclose in this Form 8-K?

The company announced it reported financial results for the quarter ended June 30, 2025 and furnished a press release as Exhibit 99.1.

Where can I find the actual financial numbers for KYMR's quarter ended June 30, 2025?

The Form 8-K references a press release furnished as Exhibit 99.1; the financial details are contained in that press release.

Is the press release in Exhibit 99.1 considered "filed"?

No. The filing expressly states the information and Exhibit 99.1 are being furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act.

What is Kymera's stock symbol and exchange?

Kymera's common stock trades under the symbol KYMR on The Nasdaq Global Market.

Who signed the Form 8-K for Kymera?

The report is signed by Nello Mainolfi, Ph.D., President and Chief Executive Officer, attesting to the submission of the exhibit.